Known targets — ChEMBL curated mechanism
AURKAAURKBCSF1RFGFR3FLT3KDRKIT
The experimentally established mechanism targets of Enmd-2076. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA known ✓ | O14965 | 16/20 | 1.00 |
| ▸ | AURKB known ✓ | Q96GD4 | 7/20 | 1.00 |
| ▸ | CSF1R known ✓ | P07333 | 2/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 2/20 | 1.00 |
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 1.00 |
| ▸ | FGFR3 known ✓ | P22607 | 2/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 2/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 2/20 | 1.00 |
| ▸ | TYK2 | P29597 | 2/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 2/20 | 1.00 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enmd-2076 SCHEMBL10122873 | 1.00 | AURKA (1.00) | AURKAAURKBNTRK1PLK4ABL1 | |
| Enmd-2076 SCHEMBL29355178 | 1.00 | AURKA (1.00) | AURKAAURKBNTRK1PLK4ABL1 | |
| Enmd-2076 SCHEMBL15668060 | 1.00 | AURKA (1.00) | AURKAAURKBNTRK1PLK4ABL1 | |
| SCHEMBL10122902 | 0.94 | AURKA (0.89) | AURKAAURKBNTRK1PLK4ABL1 | |
| Enmd-2076 SCHEMBL29379147 | 0.92 | AURKA (1.00) | AURKAAURKBNTRK1PLK4ABL1 | |
| Enmd-2076 SCHEMBL15239834 | 0.92 | AURKA (1.00) | AURKAAURKBNTRK1PLK4ABL1 | |
| Enmd-2076 SCHEMBL29381911 | 0.92 | AURKA (1.00) | AURKAAURKBNTRK1PLK4ABL1 | |
| Enmd-2076 SCHEMBL29389572 | 0.92 | AURKA (1.00) | AURKAAURKBNTRK1PLK4ABL1 | |
| SCHEMBL2499073 | 0.92 | AURKA (0.85) | AURKAAURKBNTRK1PLK4ABL1 | |
| SCHEMBL2499079 | 0.92 | AURKA (0.85) | AURKAAURKBNTRK1PLK4ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4077690-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | Engine Biosciences Pte. Ltd. (SG) | 2022-10-26 | — | — | EP | claimed |
| US-20210213037-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2021-07-15 | — | — | US | claimed |
| EP-3752161-A1 | METHODS FOR TREATING FIBROSIS | Children's Hospital Medical Center (US) | 2020-12-23 | — | — | EP | claimed |
| WO-2019161000-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2019-08-22 | — | — | WO | claimed |
| EP-2786765-B1 | Composition for combination therapy comprising an anti-C-met antibody and a FGFR inhibitor | SAMSUNG ELECTRONICS CO LTD (KR) | 2018-10-03 | — | — | EP | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4705293-A1 | SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | KARTOS THERAPEUTICS, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-8114870-B2 | Method of treating disease states using substituted pyrazole compounds | MIIKANA THERAPEUTICS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20090264422-A1 | METHOD OF TREATING DISEASE STATES USING SUBSTITUTED PYRAZOLE COMPOUNDS | MIIKANA THERAPEUTICS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264422-A1 | METHOD OF TREATING DISEASE STATES USING SUBSTITUTED PYRAZOLE COMPOUNDS | MIIKANA THERAPEUTICS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-7563787-B2 | Substituted pyrazole compounds | MIIKANA THERAPEUTICS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563787-B2 | Substituted pyrazole compounds | MIIKANA THERAPEUTICS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20070142368-A1 | Substituted pyrazole compounds | MIIKANA THERAPEUTICS, INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070142368-A1 | Substituted pyrazole compounds | MIIKANA THERAPEUTICS, INC. | 2007-06-21 | — | — | US | disclosed |
| WO-2007041358-A2 | SUBSTITUTED PYRAZOLE COMPOUNDS | MIIKANA THERAPEUTICS, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | JAK2, JAK1, MPL | AURKA 757/4885AURKB 494/4885CSF1R 529/4885 |
| US-20070142368-A1 | Substituted pyrazole compounds | AURKC, AURKA, AURKB | AURKA 2/4885AURKB 3/4885CSF1R 3545/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | AURKA 740/4885AURKB 524/4885CSF1R 1465/4885 |
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | AURKA 3234/4885AURKB 1682/4885CSF1R 442/4885 |
| US-20090264422-A1 | METHOD OF TREATING DISEASE STATES USING SUBSTITUTED PYRAZOLE COMPOUNDS | AURKC, AURKA, AURKB | AURKA 2/4885AURKB 3/4885CSF1R 3546/4885 |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | AURKA 3234/4885AURKB 1682/4885CSF1R 442/4885 |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | AURKA 3122/4885AURKB 1445/4885CSF1R 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.